• Engineered LRRK2 kinase-domain inhibitor scaffold 14m ago
  • Huntingtin polyQ-tract recognizer 14m ago
  • TDP-43 N-terminal stabilizer 14m ago
  • α-Synuclein aggregation inhibitor 14m ago
  • Anti-Aβ42 binder de novo 14m ago
  • Coverage 25%
    Whitespace 75% — that's where missions and gaps live
    1 mission 0 open gaps 100.0k funded
    paper density 19%
    hypothesis density 12%
    KG edge density 0%
    debate depth 0%
    evidence quality 32%
    citation completeness 58%
    trial coverage 50%
  • Coverage 69%
    Whitespace 31% — that's where missions and gaps live
    1 mission 0 open gaps 100.0k funded
    paper density 100%
    hypothesis density 100%
    KG edge density 0%
    debate depth 30%
    evidence quality 100%
    citation completeness 70%
    trial coverage 50%
  • Coverage 74%
    Whitespace 26% — that's where missions and gaps live
    1 mission 0 open gaps 100.0k funded
    paper density 100%
    hypothesis density 100%
    KG edge density 0%
    debate depth 85%
    evidence quality 100%
    citation completeness 67%
    trial coverage 50%
  • Coverage 74%
    Whitespace 26% — that's where missions and gaps live
    1 mission 0 open gaps 100.0k funded
    paper density 100%
    hypothesis density 100%
    KG edge density 0%
    debate depth 100%
    evidence quality 100%
    citation completeness 61%
    trial coverage 50%
  • Coverage 76%
    Whitespace 24% — that's where missions and gaps live
    1 mission 394 open gaps 100.0k funded
    paper density 100%
    hypothesis density 100%
    KG edge density 0%
    debate depth 100%
    evidence quality 100%
    citation completeness 74%
    trial coverage 50%